AMX0035 is a combination therapy designed to reduce neuronal death through blockade of key cellular death pathways originating in the mitochondria and endoplasmic reticulum (ER). This clinical trial is designed to evaluate whether the treatment is safe and able to slow decline due to ALS.
Participation will last for approximately 30-34 weeks, including 24 weeks of treatment, additional screening/baseline assessments taking up to 6 weeks, and 4 weeks of safety follow up after treatment is completed.
Site contact information will be update as sites become activated. Please visit again in the near future for up-to-date information regarding the Centaur Trial.